Biodrugs

Papers
(The median citation count of Biodrugs is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-03-01 to 2024-03-01.)
ArticleCitations
Designer Exosomes: A New Platform for Biotechnology Therapeutics123
Therapeutic siRNA: State-of-the-Art and Future Perspectives82
Cell-Free Protein Synthesis: A Promising Option for Future Drug Development63
Clinical Trials of IL-12/IL-23 Inhibitors in Inflammatory Bowel Disease57
Engineered Bacteriophage Therapeutics: Rationale, Challenges and Future57
Beyond Antibodies: The DARPin® Drug Platform52
Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy48
Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks44
Antisense Oligonucleotide Therapy: From Design to the Huntington Disease Clinic41
Immunogenicity Challenges Associated with Subcutaneous Delivery of Therapeutic Proteins41
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies38
Immunotherapy in Breast Cancer: Current Practice and Clinical Challenges36
European Stakeholder Learnings Regarding Biosimilars: Part I—Improving Biosimilar Understanding and Adoption36
The Importance of Countering Biosimilar Disparagement and Misinformation33
The Path Towards a Tailored Clinical Biosimilar Development32
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study32
European Stakeholder Learnings Regarding Biosimilars: Part II—Improving Biosimilar Use in Clinical Practice32
The Role of Immune Checkpoint Inhibitors in Colorectal Adenocarcinoma30
Ongoing Developments and Clinical Progress in Drug-Loaded Red Blood Cell Technologies29
Dengue Vaccines: An Update29
CAR-T Cell Therapy for Acute Myeloid Leukemia: Preclinical Rationale, Current Clinical Progress, and Barriers to Success29
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond28
Anti-Drug Antibody Formation Against Biologic Agents in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis28
Switching to Biosimilar SDZ-ADL in Patients with Moderate-to-Severe Active Rheumatoid Arthritis: 48-Week Efficacy, Safety and Immunogenicity Results From the Phase III, Randomized, Double-Blind ADMYRA26
Safety of Intravitreal Gene Therapy for Treatment of Subjects with Leber Hereditary Optic Neuropathy due to Mutations in the Mitochondrial ND4 Gene: The REVEAL Study25
Focused Update on AAV-Based Gene Therapy Clinical Trials for Inherited Retinal Degeneration24
The Immunotherapy Landscape in Renal Cell Carcinoma24
SARS-CoV-2 Neutralization in Convalescent Plasma and Commercial Lots of Plasma-Derived Immunoglobulin24
Recent Achievements and Challenges in Prolonging the Serum Half-Lives of Therapeutic IgG Antibodies Through Fc Engineering23
Applying Antibodies Inside Cells: Principles and Recent Advances in Neurobiology, Virology and Oncology23
Teserpaturev/G47Δ: First Approval22
Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants22
Targeted Therapies for Eosinophilic Gastrointestinal Disorders22
Novel Targeted Biological Agents for the Treatment of Atopic Dermatitis22
Certolizumab Pegol: A Review in Moderate to Severe Plaque Psoriasis20
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets20
Efficacy, Safety, and Immunogenicity of HLX02 Compared with Reference Trastuzumab in Patients with Recurrent or Metastatic HER2-Positive Breast Cancer: A Randomized Phase III Equivalence Trial20
Biosimilar Pegfilgrastim: Improving Access and Optimising Practice to Supportive Care that Enables Cure19
Monoclonal Antibody-Based Therapies for Myasthenia Gravis19
Anti-VEGF and Other Novel Therapies for Neovascular Age-Related Macular Degeneration: An Update18
Tumor in the Crossfire: Inhibiting TGF-β to Enhance Cancer Immunotherapy18
Plant-Derived Human Vaccines: Recent Developments18
Interchangeability of Biosimilars: What Level of Clinical Evidence is Needed to Support the Interchangeability Designation in the United States?18
Allergic Reactions to COVID-19 Vaccines: Risk Factors, Frequency, Mechanisms and Management18
Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities18
Calcitonin Gene-Related Peptide (CGRP)-Targeted Monoclonal Antibodies and Antagonists in Migraine: Current Evidence and Rationale18
New Insight on the Safety of Erenumab: An Analysis of Spontaneous Reports of Adverse Events Recorded in the US Food and Drug Administration Adverse Event Reporting System Database18
RNA Targeting and Gene Editing Strategies for Transthyretin Amyloidosis16
Cryopreservation of NK and T Cells Without DMSO for Adoptive Cell-Based Immunotherapy16
Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer16
Switching from One Biosimilar to Another Biosimilar of the Same Reference Biologic: A Systematic Review of Studies16
Vaccine-Associated Enhanced Viral Disease: Implications for Viral Vaccine Development15
The Role of Anti-PD-1/PD-L1 in the Treatment of Skin Cancer15
Qualitative Analysis of the Design and Implementation of Benefit-Sharing Programs for Biologics Across Europe15
Large-Scale Postmarketing Surveillance of Biological Drugs for Immune-Mediated Inflammatory Diseases Through an Italian Distributed Multi-Database Healthcare Network: The VALORE Project15
Physician Understanding and Willingness to Prescribe Biosimilars: Findings from a US National Survey15
Approval of Itolizumab for COVID-19: A Premature Decision or Need of The Hour?14
Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence14
Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)14
Regulatory Evaluation of Biosimilars: Refinement of Principles Based on the Scientific Evidence and Clinical Experience14
Nerve Growth Factor (NGF) Inhibitors and Related Agents for Chronic Musculoskeletal Pain: A Comprehensive Review13
Targeting IL-36 in Inflammatory Skin Diseases13
Efficacy, Safety and Immunogenicity of AVT02 Versus Originator Adalimumab in Subjects with Moderate to Severe Chronic Plaque Psoriasis: A Multicentre, Double-Blind, Randomised, Parallel Group, Active 13
Efficacy and Safety of Bevacizumab Biosimilar FKB238 Versus Originator Bevacizumab: Results from AVANA, a Phase III Trial in Patients with Non-Squamous Non-Small-Cell Lung Cancer (non-sq-NSCLC)12
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine12
Failed, Interrupted, or Inconclusive Trials on Immunomodulatory Treatment Strategies in Multiple Sclerosis: Update 2015–202012
A Pharmacological Batch of Mongersen that Downregulates Smad7 is Effective as Induction Therapy in Active Crohn’s Disease: A Phase II, Open-Label Study12
Efficacy, Safety, and Immunogenicity of HLX04 Versus Reference Bevacizumab in Combination with XELOX or mFOLFOX6 as First-Line Treatment for Metastatic Colorectal Cancer: Results of a Randomized, Doub11
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study11
Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders11
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status11
Impact of Obesity on Response to Biologic Therapies in Patients with Inflammatory Bowel Diseases10
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy10
Restoring Protein Expression in Neuromuscular Conditions: A Review Assessing the Current State of Exon Skipping/Inclusion and Gene Therapies for Duchenne Muscular Dystrophy and Spinal Muscular Atrophy10
Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease10
Post-Marketing Pooled Safety Analysis for CT-P13 Treatment of Patients with Immune-Mediated Inflammatory Diseases in Observational Cohort Studies9
Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials9
Current Progress and Challenges in the Study of Adjuvants for Oral Vaccines9
Serplulimab Plus Chemotherapy vs Chemotherapy for Treatment of US and Chinese Patients with Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis to Inform Drug Pricing9
Extracellular Vesicles Derived from Mesenchymal Stem Cells: A Potential Biodrug for Acute Respiratory Distress Syndrome Treatment9
PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras9
A Tale of Two New Targets for Hypertriglyceridaemia: Which Choice of Therapy?9
MYL1501D Insulin Glargine: A Review in Diabetes Mellitus9
Bioanalytical Methods and Strategic Perspectives Addressing the Rising Complexity of Novel Bioconjugates and Delivery Routes for Biotherapeutics8
Cell Therapy for Idiopathic Pulmonary Fibrosis: Rationale and Progress to Date8
CRISPR Takes the Front Seat in CART-Cell Development8
Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States8
Targeting Amyloid Fibrils by Passive Immunotherapy in Systemic Amyloidosis8
Targeted Therapy for Primary Sjögren’s Syndrome: Where are We Now?7
Retention Rate and Efficacy of the Biosimilar CT-P13 Versus Reference Infliximab in Patients with Ankylosing Spondylitis: A Propensity Score–Matched Analysis from the Korean College of Rheumatology Bi7
Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine7
Anti-HIV-1 Antibodies: An Update7
Comparative Risk of Arterial Thromboembolic Events Between Aflibercept and Ranibizumab in Patients with Maculopathy: A Population-Based Retrospective Cohort Study7
Treatment with SDZ-ADL, an Adalimumab Biosimilar, in Patients with Rheumatoid Arthritis, Psoriasis, or Psoriatic Arthritis: Results of Patient-Reported Outcome Measures from Two Phase III Studies (ADM7
Targeting the Inside of Cells with Biologicals: Chemicals as a Delivery Strategy7
Innovative Therapies for Hemoglobin Disorders7
PF-06410293: An Adalimumab Biosimilar6
The Economic Burden of CAR T Cell Therapies Ciltacabtagene Autoleucel and Idecabtagene Vicleucel for the Treatment of Adult Patients with Relapsed or Refractory Multiple Myeloma in the US6
Analytical Similarity Assessment of ABP 959 in Comparison with Eculizumab Reference Product6
Evolving Perceptions, Utilization, and Real-World Implementation Experiences of Oncology Monoclonal Antibody Biosimilars in the USA: Perspectives from Both Payers and Physicians6
Update on Biosimilar Insulins: A US Perspective6
Pharmacists’ Perspectives of Biosimilars: A Systematic Review6
Critical Analysis of cGMP Large-Scale Expansion Process in Bioreactors of Human Induced Pluripotent Stem Cells in the Framework of Quality by Design6
Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis6
Rheumatoid Arthritis Treatment Options and Type 2 Diabetes: Unravelling the Association6
Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs)6
Safety of Marketed Cancer Supportive Care Biosimilars in the US: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database6
Long-Term Safety and Effectiveness of PF-05280014 (a Trastuzumab Biosimilar) Treatment in Patients with HER2-Positive Metastatic Breast Cancer: Updated Results of a Randomized, Double-Blind Study6
Enhancing the Response Rate to Recombinant Uricases in Patients with Gout6
Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis6
Comparability of Biologics: Global Principles, Evidentiary Consistency and Unrealized Reliance5
Targeting Nuclear Export Proteins in Multiple Myeloma Therapy5
Interleukin-1 Antagonists for the Treatment of Recurrent Pericarditis5
Factors Influencing Infusion-Related Reactions Following Dosing of Reference Rituximab and PF-05280586, a Rituximab Biosimilar5
Fetal and Neonatal Adverse Drug Reactions Associated with Biologics Taken During Pregnancy by Women with Autoimmune Diseases: Insights from an Analysis of the World Health Organization Pharmacovigilan5
Anti-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer’s Disease5
Switching from Biologic to Biosimilar Products: Insight from an Integrated Health Care System5
The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland5
Checkpoint Inhibitors in Gynecological Malignancies: Are we There Yet?5
The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease5
Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospec5
Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy5
0.025836944580078